Drug Profile
NPL 2003
Alternative Names: NPL-2003Latest Information Update: 28 May 2012
Price :
$50
*
At a glance
- Originator Neuropharm
- Class Anxiolytics
- Mechanism of Action Glutamate modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obsessive-compulsive disorders
Most Recent Events
- 21 Dec 2011 Autism Therapeutics acquires Neuropharm
- 21 Dec 2011 Discontinued - Phase-II for Obsessive-compulsive disorders in USA (unspecified route)
- 12 May 2009 Phase II development is ongoing in USA